MWVC
INSY

Morgens Waterfall Vintiadis & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-120,000
Closed -$1.87M – 46
2014
Q2 		$1.87M Buy
+120,000
New +$1.94M 1.23% 27

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's INSY Position: Q3 2014 in Review

Morgens Waterfall Vintiadis & Co sold out of Insys Therapeutics, Inc. (INSY) in Q3 2014, closing a stake of 120,000 shares — an estimated $1.87M sold.

Morgens Waterfall Vintiadis & Co first reported a position in INSY in Q2 2014 and held it in 1 quarter. The position peaked at $1.87M in Q2 2014. 111 funds tracked by Wall St. Rank hold INSY as of Q3 2014.

  • Morgens Waterfall Vintiadis & Co reported no remaining Insys Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 120,000 Insys Therapeutics, Inc. shares in Q3 2014, an estimated $1.87M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Insys Therapeutics, Inc. position peaked at $1.87M in Q2 2014.
  • 111 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2014.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2014, filed 4 Nov 2014.